reports
- Daniel Wilkinson
Nuevolution - Amgen offers SEK32.50/share in cash
Amgen has announced a recommended cash offer for Nuevolution’s shares of SEK32.50/share, valuing the company at approximately SEK1,610m (US$167m). The offer represents a 169% premium to the closing price (SEK12.10) on 21 May (the day before the announcement) and a 69% premium to the highest trading price (SEK19.26) over the 52-week period (before 21 May 2019). Nuevolution’s board has unanimously recommended that shareholders accept the offer. The offer is not subject to any financing conditi...
- Daniel Wilkinson
Nuevolution - Small molecules, big ambitions
Positive progress in Nuevolution’s RORγt partnership with Almirall has triggered a €1m milestone payment (SEK10.5m) and we continue to forecast that it will enter the clinic in 2019. FY18 was defined by the progress in the Amgen partnership as it opted in for two oncology programmes, further validating Nuevolution’s Chemetics technology. In Nuevolution’s BET-BD1 programme, a development candidate (NUE20798) has been nominated; data in animal cancer models highlight that it may have syne...
Nuevolution - Pipeline and partnerships continue to strengthen
With the completion of the up-listing to the Nasdaq Stockholm main market and the successful gross SEK110m capital raise, Nuevolution continues to strengthen both its investor base and financial position. Amgen’s opt-in on the first programme in its multi-target collaboration and the identification of much sought-after small-molecule IL-17A inhibitors continue to validate Nuevolution’s Chemetics technology. Its transition to a clinical asset-focused company continues with the Almirall RORγt...
- Daniel Wilkinson
Nuevolution - Pipeline and strategic execution drives prospects
Nuevolution’s 2017 was defined by internal progress of the RORγt inhibitor and BET-BD1 programmes (expected to be clinically ready in 2019). In 2018 we anticipate value will be driven by new and existing partners, for example we expect Almirall to initiate a RORγt inhibitor Phase I trial in late 2018, making it the first Nuevolution product candidate to enter the clinic. In addition to existing collaborations, a new partnership is anticipated by Nuevolution in the next three to nine months. ...
- Daniel Wilkinson
Nuevolution - On the road to becoming a clinical company
July to September 2017 results highlight the continued progression of Nuevolution into a clinical company. Ongoing partnerships with Almirall, Amgen and Janssen continue to advance as we expect and we anticipate that Almirall’s RORγt inhibitor programme will be the first Nuevolution asset to enter the clinic (in dermatology and psoriatic arthritis), which we forecast for H218/H119. Lead assets in the internal pipeline are nearing clinical readiness and Nuevolution anticipates a new partnershi...
- Daniel Wilkinson
- Defining year as partnerships progress on track
FY17 has been a defining year for Nuevolution as it looks to further validate its unique Chemetics drug discovery platform. Highlights include the Amgen development collaboration, out-licensing the RORγt inverse agonist (dermatology and psoriatic arthritis indications) to Almirall and the progression of the internally generated pipeline assets. We anticipate at least one further out-licensing or risk-sharing collaboration in FY18. We value the company's recent deals with Amgen, Almirall and Jans...
- Susie Jana
Chemetics proof is in the deal making
Nuevolution’s proprietary Chemetics DNA-encoded screening platform technology enables fast and accurate small molecule drug discovery. The technology has received powerful external validation, including two recent collaborations (Amgen and Almirall) that could generate significant value in the coming years. In addition, we expect Nuevolution to progress at least one internally generated asset into clinical development in the near future. We value the company's recent deals with Amgen and Almiral...
- Susie Jana
Delivering on promises
The Almirall deal announced on 12 December tops a defining year for Nuevolution; it has delivered on two key IPO promises, signing at least one licensing agreement (Almirall) and one risk-sharing collaboration (Amgen) within 12-18 months of IPO. The Almirall deal focuses on the development and commercialisation of RORγt inverse agonist for dermatological diseases and psoriatic arthritis. An upfront of €11.2m (SEK109.4m) contributes to a total potential deal value of €453.2m (SEK4.4bn). Added to ...
Ford Equity International Rating and Forecast Report
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Nuevolution: Conference Call to Discuss the Strategic Collaboration wi...
STOCKHOLM--(BUSINESS WIRE)-- Nuevolution AB (publ) (NUE.ST) announce that the company’s executive management will host a conference call and webcast to discuss the strategic collaboration with Almirall on Monday 12 December at 14:00 CET. Access to the event can be obtained as follows: LIVE access on Monday 12 December at 14:00 CET Telephone numbers: SE: +46 85 664 2690 DK: +45 3544 5575 UK: +44 20 3008 9802 US: +1 855 831 5945 Webcast will be available...
Almirall and Nuevolution Enter into a Strategic Collaboration to Devel...
BARCELONA, Spain & STOCKHOLM--(BUSINESS WIRE)-- Almirall S.A. and Nuevolution A/S (a wholly owned subsidiary of Nuevolution AB (publ)) (STO:NUE) announced today that they have entered into a global strategic collaboration focusing on the development and commercialization of Nuevolution’s novel RORγt inverse agonist (inhibitor) program for treatment of inflammatory skin diseases and disorders as well as for treatment of psoriatic arthritis. As part of the agreement, the parties will also establish a research collaboration for ...
- Daniel Wilkinson
Amgen deal: A significant step forward
The strategic collaboration with Amgen provides further validation of Nuevolution’s Chemetics drug discovery platform. With up to $410m per development programme and a tiered royalty rate, the deal could generate significant value in the coming years. Cash of c SEK176m ($19.4m) at 30 September 2016, along with revenue from collaborations and licensing agreements, will enable Nuevolution to continue to expand its internal pipeline. We anticipate its lead internal candidate RORγt and possibly anot...
- Daniel Wilkinson
Amgen deal: A significant step forward
The strategic collaboration with Amgen provides further validation of Nuevolution’s Chemetics drug discovery platform. With up to $410m per development programme and a tiered royalty rate, the deal could generate significant value in the coming years. Cash of c SEK176m ($19.4m) at 30 September 2016, along with revenue from collaborations and licensing agreements, will enable Nuevolution to continue to expand its internal pipeline. We anticipate its lead internal candidate RORγt and possibly anot...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.